New Mental Health Program Available

MSAA has partnered with Talkspace, an online mental health service, to create an innovative pilot program for individuals with MS to receive three months of online therapy at no cost. Talkspace connects people to thousands of dedicated providers via a secure and confidential, HIPAA-compliant platform.

Read News Article

The Multiple Sclerosis Association of America Proudly Announces the 9th Annual Improving Lives Benefit in Support of the MS Community 

The Multiple Sclerosis Association of America (MSAA) is excited to gather together for our 9th Annual Improving Lives Benefit this May. We are delighted to announce two opportunities to attend, including an in-person reception and a virtual program highlighting key members of the MS community.

Read News Article

The Multiple Sclerosis Association of America (MSAA) Focuses on MS at All Stages of Life During MS Awareness Month

The Multiple Sclerosis Association of America (MSAA) proudly recognizes March as Multiple Sclerosis Awareness Month and is pleased to present four weeks full of valuable and inspiring resources, programs, and strategies for all ages. We are dedicated to spreading awareness, education, and support to individuals, families, and care partners in the MS community, and this month is no different.

Read News Article

What’s New in MS Research – January 2023

The studies featured in this edition of “What’s New in MS Research” speak to progress made and progress awaited. We start out by announcing two new disease-modifying therapies that are or soon will be available through one’s healthcare provider.

Read News Article

FDA Approves Briumvi for the Treatment of Relapsing Forms of MS

TG Therapeutics has announced that the United States Food and Drug Administration (FDA) approved Briumvi™ (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (MS) in adults – including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS. This medication is a monoclonal antibody that targets CD20, a protein found on the surface of B cells, and induces B-cell depletion within 24 hours. B cells are white blood cells shown to play a role in MS.

Read News Article

What’s New in MS Research – November 2022

Experts in every aspect of multiple sclerosis (MS) gathered in Amsterdam, The Netherlands, in late October 2022 to unveil research results and share ideas at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). With more than 1,200 bridges, the Dutch capital was an appropriate location for a meeting dedicated to connecting the findings from laboratory research and clinical trials to enhancements in patient care.

Read News Article

In Remembrance: Jack Burks, MD

On Friday, November 18, 2022, …

Read News Article

What’s New in MS Research – September 2022

If there’s one theme that emerges from the study findings that follow, it’s how much people with multiple sclerosis (MS) can do to enhance their health and wellbeing. We know that can be a challenging task, as many aspects of the disease and its course remain beyond a person’s control. Nonetheless, the research summarized here provides abundant reason for encouragement.

Read News Article

The Multiple Sclerosis Association of America (MSAA) Launches Comprehensive Tool for the MS Community to Learn about Treatment Options

The Multiple Sclerosis Association of America (MSAA) is proud to announce the launch of the Ultimate MS Treatment Guide – a unique and comprehensive tool to help people with multiple sclerosis learn about the different FDA-approved disease-modifying therapies. This online resource for the MS community, which can be accessed at MStreatmentguide.org, has been developed by MSAA in collaboration with Wondros, a global creative agency.

Read News Article